Glaucoma Pharmaceuticals Market Key Highlights:
- Market Size (2024): USD 2,361 Million
- Projected Market Size (2034): USD 2,873 Million
- CAGR (2023-2034): 1.8%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Glaucoma Pharmaceuticals Market Definition
The glaucoma pharmaceuticals market deals in the manufacturing and distribution of therapies for treating chronic eye diseases worldwide. Various types of medicines are used in the treatment of this disease, including alpha-adrenergic agonists, carbonic anhydrase inhibitors, combination drugs, and others. This market is projected to rise significantly with the growth of the biopharmaceutical industry worldwide.
The growing cases of diabetes worldwide and the rise in the geriatric population have increased the demand for glaucoma therapeutics, thereby driving market growth. Also, the rising use of smartphones and laptops has increased the prevalence of glaucoma, which requires effective medicine to get cured, boosting industrial expansion. Moreover, the growing application of glaucoma drugs in hospitals, ophthalmic clinics, ambulatory surgical centers, and some others, along with the rising adoption of prostaglandins analogs for treating this disease, is expected to boost the growth of the glaucoma pharmaceuticals market.
Advancements in minimally invasive glaucoma surgery (MIGS), along with developments in technologies such as optical coherence tomography (OCT) and selective laser trabeculoplasty (SLT), are expected to create ample growth opportunities for the market players in the upcoming days. In February 2024, Glaukos launched iDose TR (travoprost intracameral implant). iDose TR (travoprost intracameral implant) is an effective therapy used in the treatment of ocular hypertension or open-angle glaucoma.
Glaucoma Pharmaceuticals Market Segmentation:
By Type
- Prostaglandins Analogues (PGAs)
- Non PGAs
By Application
- Hospital Pharmacies
- Private Clinics
- Drug Stores
- Retail Pharmacies
- E-Commerce
Glaucoma Pharmaceuticals Market Companies:
- Acadia Pharmaceuticals Inc.
- Allergan Inc.
- Inotek Pharmaceuticals Corporation
- Merck & Co. Inc.
- Santen Pharmaceutical Co.Ltd.
- Novartis International AG.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
